Itacitinib in Advanced Hepatocellular Carcinoma (JAKaL)

  • days left to enroll
  • participants needed
  • sponsor
    Imperial College London
Updated on 4 October 2022


This research will assess the effects of Itacitinib as a second line treatment for patients with advanced inflammatory hepatocellular carcinoma (HCC), a type of liver cancer. Itacinib is a protein inhibitor of the tyrosine kinase, JAK1, which is believed to enable cancer cells to metastasise to other parts of the body.


JAKaL is a single arm phase Ib study evaluating the effect of Itacitinib in 25 patients with advanced HCC.

Many patients diagnosed with HCC will have advanced disease where only palliative care is offered to them, this could account for the relatively low reported 5-year survival rate of approximately 10%. There are a number of epidemiological and pre-clinical studies that have investigated the role of chronic inflammatory conditions in the development of HCC and these provide evidence that inflammation promotes malignant transformation. The production of tumour-promoting cytokines by inflammatory cells can activate transcription factors, such as STAT3 via the JAK/STAT pathway in premalignant cells. STAT3, once activated, can cause the expression of further genes necessary for cell activation, localisation, survival and proliferation. Inhibition of JAK could therefore be a way of directly affecting malignant cell proliferation, as STAT3 in most malignancies are persistently phosphorylated and thereby stimulated to carry out its function; to sustain cell proliferation and block apoptosis.

For reference, STAT3 is a member of the STAT protein family and is switched on, via phosphorylation, by receptor-associated Janus kinases (JAK), a type of tyrosine kinase, and together they form homo-/heterodimers that translocate to the cell nucleus and act as transcription activators. STAT3 mediates the expression of a variety of genes and therefore is integral to many cellular processes, as mentioned above, such as cell growth and apoptosis, and thus they can promote oncogenesis by being over-active in the different signalling pathways it is involved in.

Itacitinib has not yet been approved by the U.S. Food and Drug Administration (FDA) for any clinical indication but has been developed as potential treatments for myelofibrosis (MF), rheumatoid arthritis (RA), psoriasis, graft-versus-host disease (GVHD), B cell malignancies and solid tumours like HCC. It is a small molecule selective inhibitor of JAK1 thereby preventing its phosphorylation of STAT proteins, particularly STAT3, resulting in a decrease in the expression of genes responsible for cell activation, localisation, survival and proliferation

Condition Advanced Hepatocellular Carcinoma
Treatment Itacitinib (INCB039110)
Clinical Study IdentifierNCT04358185
SponsorImperial College London
Last Modified on4 October 2022


Yes No Not Sure

Inclusion Criteria

Aged 18 or over
Diagnosis of hepatocellular carcinoma. If primary diagnosis of HCC: diagnosis based on the following criteria
cyto-histological criteria, OR
radiological criteria: Focal lesion >1 cm with arterial hypervascularization in 2 coincident imaging techniques (CT, MRI, or US), OR
combined criteria: one imaging technique showing a focal lesion 1-2 cm with arterial hypervascularization AND AFP levels >400 ng/mL, OR
combined criteria: one imaging technique showing a focal lesion >2 cm with arterial hypervascularization AND AFP levels >200 ng/mL
Child-Pugh A and B up to 7 points (in patients receiving anticoagulant therapy
Progression or intolerance to first line therapy - N.B: Date of patients last dose of therapy must be more than 28 days before enrolment into this study
Child-Pugh score up to 5 points; INR category not regarded for calculation of
ECOG Performance status 0, 1 or 2
the Child-Pugh score)
Adequate organ function as defined by
Adequate hematologic function (ANC 1.0x109/l, platelet count 50x109/l, and hemoglobin 9g/dl)
Serum creatinine concentration < 1.5 times the upper limit of normal (ULN) and/or creatinine clearance >60 ml/min
Bilirubin level < 1.5 X ULN
For women of child-bearing potential (defined as women who have not undergone surgical
sterilization with a hysterectomy, and/or bilateral oophorectomy, and are not
postmenopausal, defined as ≥12 months of amenorrhea) must have a negative
serum pregnancy test within 14 days prior to the first study drug
administration Effective contraception must be used throughout the duration of
the study and up to 30 days following the last dose of the investigational
medicinal product (IMP). Effective forms of contraception include complete
abstinence from sexual intercourse, double barrier methods (condom with
spermicide in conjunction with use of an intrauterine device or condom with
spermicide in conjunction with use of a diaphragm), birth control patch or
vaginal ring, oral, injectable, or implanted contraceptives and surgical
sterilization (tubal ligation or vasectomy). Sperm and ova donation are
prohibited during the duration of the study and 30days after the last dose. 8
Written informed consent prior to initiation of any study procedures and
willing and able to comply with the study schedule

Exclusion Criteria

Previous treatment with
Study medication, any other JAK1 inhibitor and/or known hypersensitivity to the study medication
An investigational agent within 28 days prior to start of study treatment
Serious concurrent medical or psychiatric illness, including serious active infection
Uncontrolled ascites
Uncontrolled hypertension
History of organ transplant (including prior liver transplant)
Diagnosis of HIV, congenital immune defect, any immunosuppressive therapy for autoimmune disease or inflammatory bowel disease
Patients with active or latent tuberculosis
Patients with active hepatitis C or active hepatitis B that requires treatment
Patients who have received a live vaccine 30 days or fewer prior to enrolment as well as patients who intend to receive live vaccination during study participation or for three months after last dose administration
Patients who have a history of unprovoked venous thromboembolism (VTE) prior to the diagnosis of malignancy 9. Pregnant or breast feeding women Other clinically significant co-morbidities that could compromise the subject's participating in the study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note